Primary Peritoneal Cancer Clinical Trials in Atlanta, Georgia

4 studies are recruiting for primary peritoneal cancer in Atlanta, Georgia right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)

   The main goals of this study are to learn about the safety of sacituzumab tirumotecan with bevacizumab and if people tolerate it; and if people who take sacituzumab tirumotecan with or without bevacizumab live longer without the cancer getting worse than those who receive standard of care treatment.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Winship Cancer Institute of Emory University ( Site 0086), Atlanta, Georgia

   Locations

   196 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT06824467 on ClinicalTrials.gov

2. Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

   The OnPrime study is a multi-center, randomized open-label phase 3 study evaluating the safety and efficacy of Olvi-Vec followed by platinum-doublet chemotherapy and bevacizumab compared to the Active Comparator Arm with Physician's Choice of chemotherapy and bevacizumab in women diagnosed with pla…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Emory University, Atlanta, Georgia

   Locations

   33 in total

   Run by

   Genelux Corporation

   See if you can join NCT05281471 on ClinicalTrials.gov

3. A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors

   This is an open-label, multicenter phase 1 study to evaluate the safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0505 in Adult Participants with Advanced Solid Tumors

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Emory Winship Cancer Institute, Atlanta, Georgia

   Locations

   17 in total

   Run by

   NextCure, Inc.

   See if you can join NCT06792552 on ClinicalTrials.gov

4. A Beta-only IL-2 ImmunoTherapY Study

   This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of anti-tumor activity of MDNA11 alone or in combination with a checkpoint inhibitor in patients with advanced solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Emory - Winship Cancer Institute, Atlanta, Georgia

   Locations

   27 in total

   Run by

   Medicenna Therapeutics, Inc.

   See if you can join NCT05086692 on ClinicalTrials.gov